睿智医药
(300149)
| 流通市值：44.51亿 | | | 总市值：46.71亿 |
| 流通股本：4.75亿 | | | 总股本：4.98亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 266,689,812.56 | 1,134,719,476.3 | 816,848,135.12 | 533,797,976.84 |
| 营业收入 | 266,689,812.56 | 1,134,719,476.3 | 816,848,135.12 | 533,797,976.84 |
| 二、营业总成本 | 289,479,241.79 | 1,116,539,022.01 | 815,922,997.79 | 513,553,112.14 |
| 营业成本 | 207,628,832.5 | 810,025,161.14 | 591,783,360.36 | 378,921,265.51 |
| 税金及附加 | 1,033,872.09 | 3,810,288.92 | 3,262,638.7 | 2,125,771.08 |
| 销售费用 | 17,232,191.76 | 61,482,482.96 | 42,602,703.7 | 25,031,453.84 |
| 管理费用 | 40,162,290.43 | 171,888,522.28 | 131,238,406.62 | 81,833,011.13 |
| 研发费用 | 15,514,256.51 | 59,841,693.85 | 41,853,143.7 | 24,722,034.39 |
| 财务费用 | 7,907,798.5 | 9,490,872.86 | 5,182,744.71 | 919,576.19 |
| 其中:利息费用 | 1,840,611.07 | 15,863,827.26 | 12,569,317.7 | 8,318,536.93 |
| 其中:利息收入 | 1,969,689.33 | 9,855,076.83 | 7,556,805.19 | 5,413,857.93 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -44,385.66 | - | -10,500.74 | -15,167.73 |
| 加:投资收益 | -71,540.01 | 12,154,847.66 | 13,835,351.4 | 12,893,493.74 |
| 资产处置收益 | 0 | -41,843.85 | 6,273,964.72 | 6,261,722.68 |
| 资产减值损失(新) | 336,209.76 | 3,168,166.45 | 317,628.4 | -1,635,582.6 |
| 信用减值损失(新) | -2,717,142.65 | -21,802,341.74 | -16,777,280.28 | -12,808,391.56 |
| 其他收益 | 1,969,689.33 | 11,427,858.87 | 9,364,632.29 | 6,730,733.46 |
| 四、营业利润 | -23,316,598.46 | 23,087,141.68 | 13,928,933.12 | 31,671,672.69 |
| 加:营业外收入 | 17,191.52 | 2,357,255.94 | 1,378,500.54 | 917,336.1 |
| 减:营业外支出 | 139,496.82 | 9,432,364.84 | 557,946.26 | 478,061.71 |
| 五、利润总额 | -23,438,903.76 | 16,012,032.78 | 14,749,487.4 | 32,110,947.08 |
| 减:所得税费用 | -5,410,957.81 | 2,458,978.45 | 7,587,430.75 | 6,765,580.85 |
| 六、净利润 | -18,027,945.95 | 13,553,054.33 | 7,162,056.65 | 25,345,366.23 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -18,027,945.95 | 13,553,054.33 | 7,162,056.65 | 25,345,366.23 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -18,156,468.5 | 13,412,160.63 | 7,091,301.27 | 25,382,118.44 |
| 少数股东损益 | 128,522.55 | 140,893.7 | 70,755.38 | -36,752.21 |
| 扣除非经常损益后的净利润 | -19,750,251.33 | -2,863,292.88 | -14,349,544.18 | 6,792,287.51 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.04 | 0.03 | 0.01 | 0.05 |
| (二)稀释每股收益 | -0.04 | 0.03 | 0.01 | 0.05 |
| 八、其他综合收益 | -9,785,903.53 | -5,336,908.18 | -2,279,583.73 | -374,978.77 |
| 归属于母公司股东的其他综合收益 | -9,785,903.53 | -5,336,908.18 | -2,279,583.73 | -374,978.77 |
| 九、综合收益总额 | -27,813,849.48 | 8,216,146.15 | 4,882,472.92 | 24,970,387.46 |
| 归属于母公司股东的综合收益总额 | -27,942,372.03 | 8,075,252.45 | 4,811,717.54 | 25,007,139.67 |
| 归属于少数股东的综合收益总额 | 128,522.55 | 140,893.7 | 70,755.38 | -36,752.21 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-30 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |